Abstract. The Bayesian approach is being used increasingly in medical research. The flexibility of the Bayesian approach allows for building designs of clinical trials that have good properties of any desired sort. Examples include maximizing effective treatment of patients in the trial, maximizing information about the slope of a dose–response curve, minimizing costs, minimizing the number of patients treated, minimizing the length of the trial and combinations of these desiderata. They also include standard frequentist operating characteristics when these are important considerations. Posterior probabilities are updated via Bayes ’ theorem on the basis of accumulating data. These are used to effect modifications of the trial’s course, inc...
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials...
The aim of phase II single-arm clinical trials of a new drug is to determine whether it has sufficie...
There are two practical challenges in the phase I clinical trial conduct: lack of transparency to ph...
Includes bibliographical references (p. 123-128).The process of conducting a pharmaceutical clinical...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
Includes bibliographical references (p. 112-117).The efficacy, safety, and cost of pharmaceutical pr...
The rise of evidence-based medicine as well as important progress in statistical methods and computa...
Background Adaptive designs offer added flexibility in the execution of clinical tri...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
The gold of biostatistical researches is to develop statistical tools that improves human health or ...
Background Bayesian statistics are an appealing alternative to the traditional frequentist approach ...
Bayesian adaptive designs are emerging as popular approach to develop adaptive clinical trials. In t...
Hommel (Biometrical Journal; 45:581–589) proposed a flexible testing procedure for seamless phase II...
Background: Adaptive designs offer added flexibility in the execution of clinical trials, including ...
A balanced treatment of the theories, methodologies, and design issues involved in clinical trials u...
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials...
The aim of phase II single-arm clinical trials of a new drug is to determine whether it has sufficie...
There are two practical challenges in the phase I clinical trial conduct: lack of transparency to ph...
Includes bibliographical references (p. 123-128).The process of conducting a pharmaceutical clinical...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
Includes bibliographical references (p. 112-117).The efficacy, safety, and cost of pharmaceutical pr...
The rise of evidence-based medicine as well as important progress in statistical methods and computa...
Background Adaptive designs offer added flexibility in the execution of clinical tri...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
The gold of biostatistical researches is to develop statistical tools that improves human health or ...
Background Bayesian statistics are an appealing alternative to the traditional frequentist approach ...
Bayesian adaptive designs are emerging as popular approach to develop adaptive clinical trials. In t...
Hommel (Biometrical Journal; 45:581–589) proposed a flexible testing procedure for seamless phase II...
Background: Adaptive designs offer added flexibility in the execution of clinical trials, including ...
A balanced treatment of the theories, methodologies, and design issues involved in clinical trials u...
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials...
The aim of phase II single-arm clinical trials of a new drug is to determine whether it has sufficie...
There are two practical challenges in the phase I clinical trial conduct: lack of transparency to ph...